Neuron23
A clinical-stage biotech company focused on developing precision medicines for genetically defined neurological and immunological diseases.
Neuron23 combines advances in human genetics with a drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for diseases. The USA-based company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases.
Latest Neuron23 News & Features
23 August 2023
16 December 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze